Royalty Pharma plc, headquartered in New York City and founded in 1996, operates within the United States as a key player in the biopharmaceutical industry. The company primarily focuses on the acquisition of royalties from biopharmaceutical products and actively invests in funding new developments and innovations in the sector. Its activities involve diligently identifying, evaluating, and securing royalty agreements for a wide array of biopharmaceutical therapies.